Deutsche Märkte öffnen in 2 Stunden 35 Minuten

TG Therapeutics, Inc. (TGTX)

NasdaqCM - NasdaqCM Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
15,05-0,17 (-1,12%)
Börsenschluss: 04:00PM EDT
15,00 -0,05 (-0,34%)
Nachbörse: 04:48PM EDT

TG Therapeutics, Inc.

3020 Carrington Mill Blvd.
Suite 475
Morrisville, NC 27560
United States
212 554 4484
https://www.tgtherapeutics.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter264

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Michael S. Weiss Esq.Chairman, CEO & President1,97MN/A1966
Mr. Sean A. Power CPACFO, Corporate Secretary & Treasurer652,6kN/A1982
Jenna BoscoSenior Vice President of Corporate CommunicationsN/AN/AN/A
Mr. Adam WaldmanChief Commercialization OfficerN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Corporate Governance

TG Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. März 2024, lautet 10. Die grundlegenden Scores sind Audit: 4, Vorstand: 10, Shareholderrechte: 5, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.